Evernow’s progesterone page places the hormone within an ongoing menopause-care service. That can help someone decide what to ask a clinician, but it should not be read as a complete product specification. The page raises questions about brands and approval without providing their answers in the public text available for this assessment. The unanswered details are important when the question concerns an oral capsule.
Reviewed September 29, 2026, this assessment considers Evernow’s treatment and access descriptions. It does not establish which preparation an individual would receive or whether a particular plan covers it. No account, prescription, consultation or delivery was tested.
In this article
A treatment-specific page still has a formulation boundary
Evernow’s progesterone page explicitly offers clinician-guided care that can include this hormone. It discusses uterine-lining protection, bleeding, mood and sleep. This is evidence of a relevant clinical service, rather than merely an unrelated health article. It does not establish an exact oral product in the material reviewed here.
The page displays questions about prescribed brands and FDA approval, but the corresponding answers were not available in the reviewed text. That gap cannot be filled from a search headline or another service’s catalog. Ask the clinician for the actual medicine, route and manufacturer. Alloy’s review shows how a named pill listing can provide more product detail while still leaving dispensing questions open.
Protection language must connect to the entire hormone plan
The Evernow description presents progesterone as part of some estrogen treatment plans. Whether that is the reason for a particular prescription depends on the clinical situation and the other treatment being used. The presence of the word progesterone on a webpage does not determine which route or arrangement would fulfill the intended purpose.
The medicine-role guide focuses on obtaining that explanation. FDA guidance discusses the uterine-lining risk associated with estrogen for someone with a uterus and the benefit-risk discussion around hormone therapy. It does not supply an Evernow prescribing decision, and this review gives no instructions for adding, replacing or omitting a medicine.
Ninety days of platform access is not ninety capsules
Evernow’s how-it-works page describes a pay-per-visit option without membership that includes access to prescriptions and the care platform for ninety days. Separately, membership starts at $35 per month and describes continuing access, messaging and automated refills during membership. These are different descriptions of a care relationship.
Neither establishes the number of progesterone capsules dispensed or the medicine charge included in a specific transaction. The page says prescriptions may go to a pharmacy or be delivered, with many medicines covered by insurance. Confirm the actual prescription cost, visit responsibility and membership billing commitment. A starting monthly care figure should not be presented as the price of a selected oral product.
The missing ingredient list deserves a direct pharmacy question
No manufacturer-specific excipient list was established by the Evernow product material. That matters because the active hormone and the rest of a capsule are separate parts of its identity. An ingredient concern should be answered using the label for the supplied preparation, not an assumption about what progesterone usually contains.
For comparison, the Prometrium record identifies peanut oil and gelatin and includes a peanut-allergy restriction. This does not demonstrate that Evernow supplies Prometrium. The capsule-ingredient guide helps make the request specific: obtain the product name and manufacturer, then ask the dispensing professional to review the full ingredients and relevant restrictions.
A sleep testimonial cannot resolve tolerability
Evernow’s page contains member accounts about symptoms and sleep. Those accounts do not establish the effect of a particular oral progesterone preparation, especially when other hormones or aspects of care may be involved. They also cannot predict how someone else will feel during activities requiring attention.
The oral progesterone information from MedlinePlus discusses dizziness and drowsiness. Our practical drowsiness guide can help organize questions for the prescribing team about work, travel or other medicines. A clinician should assess an unwanted effect; a review should neither dismiss it as evidence of success nor suggest that the reader change the amount or timing independently.
Continuous access still needs a defined contact arrangement
The service page advertises secure messaging and optional video visits, while the one-time and membership routes have different durations of access. Messaging availability is useful information, but it is not a verified promise of an immediate clinical response, a replacement for emergency services or unlimited access after a plan ends.
Before relying on the service for later capsule questions, clarify where a pharmacist’s dispensing question and a clinician’s treatment question should go. Our follow-up guide keeps those responsibilities visible. Cancellation notice, selected renewal charge and refund conditions were not established by these pages, so those terms need a separate written answer before a recurring purchase.
Compare a specified preparation rather than an attractive category
The progesterone offering establishes an opportunity to discuss treatment. Its practical value for an individual will depend on a clinical assessment and a sufficiently specific prescription, including the medicine’s intended role and the label that accompanies it. Lack of a public ingredient list is a limit of this review, not proof that the service cannot provide one.
Midi’s review provides a particularly useful comparison because its separate capsule page names a compounded preparation and particular inactive ingredients. That extra detail should be examined on its own terms, without assuming Evernow supplies an equivalent product. The next useful answer is the exact proposed prescription, not an inferred winner between membership models.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Evernow: progesterone careProvider treatment-specific service; brand and approval FAQ questions appear without answers in retrieved text, exact dispensed oral form and ingredients unconfirmed · Checked 2026-09-29
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- Evernow: how care worksProvider one-time versus membership access;90-day platform access not medication quantity, starting membership price not medicine price · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
- MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29